Mesoblast (NASDAQ:MESO) Shares Pass Above 50-Day Moving Average – Should You Sell?

Mesoblast Limited (NASDAQ:MESO) crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $14.93 and traded as high as $15.77. Mesoblast shares last traded at $15.31, with a volume of 188,306 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mesoblast in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy”.

Mesoblast Price Performance

The company has a debt-to-equity ratio of 0.10, a current ratio of 1.58 and a quick ratio of 1.41. The company has a fifty day moving average price of $14.93 and a 200 day moving average price of $15.73. The company has a market capitalization of $1.98 billion, a P/E ratio of -54.68 and a beta of 2.08.

Institutional Trading of Mesoblast

Hedge funds have recently bought and sold shares of the company. Legal & General Group Plc acquired a new stake in shares of Mesoblast in the third quarter valued at approximately $10,501,000. Goldman Sachs Group Inc. bought a new position in shares of Mesoblast in the first quarter worth $3,209,000. Bank of America Corp DE increased its holdings in shares of Mesoblast by 791.7% during the third quarter. Bank of America Corp DE now owns 111,459 shares of the company’s stock valued at $1,796,000 after purchasing an additional 98,960 shares during the period. Brooklyn Investment Group acquired a new position in shares of Mesoblast during the third quarter valued at $655,000. Finally, Quadrature Capital Ltd bought a new stake in shares of Mesoblast during the fourth quarter valued at about $479,000. 1.43% of the stock is currently owned by institutional investors.

About Mesoblast

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.